Enbio KRX:352940KOSDAQ
인바이오 · Korean news coverage and regulatory filings, organized.
In Q3 2026, Enbio reported revenue of ₩4.2bn, up 7.5% year on year, and an operating loss of ₩1.9bn. Enbio (인바이오) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Filing signals Insider buying Dilution risk Screener
Enbio at a glance from DART filings
- Results trend
- Operating profit in 2 of the last 4 quarters; Q3 2026 operating loss of ₩1.9bn swung to a loss from a profit in the previous quarter.
- Ownership changes
- 9 5%-holder and insider ownership reports in the past 120 days (9 increases, 0 decreases).
- Capital & buybacks
- Decisions in the past year: convertible bonds ×1.
Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.
Enbio today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 135 days · period ending Dec 2026
- Oct 12 Convertible bond conversion opensin 330 days · 720,461 new shares · 6.63% dilution · price ₩2,082
Dates Enbio stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
Enbio quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩4.2bn | +7.5% | −₩1.9bn margin −45.5% | −₩1.5bn |
| Q2 2026 | ₩10.4bn | +22.5% | ₩172m margin 1.6% | −₩41m |
| Q1 2026 | ₩14.1bn | +2.2% | ₩3.1bn margin 22.1% | ₩2.2bn |
| Q4 2025 derived | ₩7.7bn | +48.3% | −₩729m margin −9.5% | −₩482m |
| Q3 2025 | ₩3.9bn | -34.8% | −₩1.3bn margin −34.1% | −₩1.1bn |
| Q2 2025 | ₩8.5bn | -3.5% | −₩167m margin −2.0% | ₩182m |
| Q1 2025 | ₩13.8bn | -11.4% | ₩3.2bn margin 22.8% | ₩2.4bn |
| Q4 2024 derived | ₩5.2bn | +13.6% | −₩2.2bn margin −42.2% | −₩1.8bn |
Enbio ranks #1955 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Enbio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Enbio news Korean headlines
-
Inbio invests 3 billion won in Alteogen LAB to expand bio new material business
4 more on this story · 4 outlets
- Inbio invests 3 billion won in Alteogen LAB to expand bio new material business알파경제 · Sep 16 10:07
- Inbio invests 3 billion won in Alteogen LAB to expand bio new material R&D더바이오 · Sep 16 10:28
- Inbio invests 3 billion won in Alteogen LAB뉴스핌 · Sep 16 10:44
- Inbio makes 3 billion won strategic investment in Alteogen LAB to expand new material business이데일리 · Sep 16 11:25